Section 1: coronaviruses (incl SARS-CoV and MERS), the structure (sequence), mechanism of action 1. Origin of SARS-CoV-2 2. SARS-CoV-2: Insights into the genome structure 3. Mechanism of binding and infection: Role of the Spike Glycoprotein 4. ACE2 in SARS-CoV-2 infectivity 5. Population-Specific Polymorphisms and SARS-CoV-2 Infectivity 6. SARS-CoV-2, SARS-CoV, and MERS-COV: similarities and differences in origin and transmission Section 2: Immune Response to COVID-19 and its effects on various organs 7. Characterization of the immune response with viral attack 8. Immune Responses and COVID-19 severity 9. Seroconversion and Adaptive Immunity to COVID-19 10. Organ specific immune related changes with COVID-19 11. Blocking immune pathways in COVID-19 12. Immune Response in Fatal COVID-19 Section 3: "Clinical manifestations based on reports from clinical observations and postmortem studies 13. Postmortem Examination of COVID-19 Lungs and Heart 14. Renal Histopathological Analysis Kidney 15. Postmortem Neuropathology in COVID-19 16. Microcirculation Section 4: The blood vessels and COVID-19: Vascular dysfunction, coagulopathies 17. Vascular manifestations of COVID-19: endothelial dysfunction and damage 18. Vasculitis and proinflammatory cascades with COVID-19 19. D-dimer in systemic circulation and COVID-19 outcome 20. Hypercoagulability in COVID-19 Section 5: Neuro-COVID-19 and its long-term implications 21. COVID and the nervous system: Mechanisms and Consequences 22. Neuroinflammation with COVID-19: single cell and model studies 23. Neurologic and Psychiatric outcome in survivors Section 6: Should COVID-19 concern nephrologists? Why and to what extent?" 24. Mechanisms that drive in acute kidney injury with COVID-19 25. Models and cellular monolayers to study effect of SARS-CoV-2 on kidney 26. Renal Manifestations of COVID-19 in the Clinic Section 7: Long COVID-19 (long term effects summarizing of clinical reports in literature) 27. Long COVID or post-acute sequalae of COVID: An introduction 28. Mechanisms and Risk factors 29. Characterizing Long COVID-19: Lessons in the clinic 30. Risk factors and Management Section 8: The vaccines 31. COVID-19: The vaccine development strategies 32. mRNA vaccines: The new frontier 33. Safety and Efficacy: A comprehensive review Section 9: Public health handling (lessons from the US, EU, Brazil, China, India etc.) 34. US 35. EU 36. Brazil 37. China 38. India Section 10: From the Editors' desk 39. The COVID-10 pandemic: Lessons Learnt 40. Current and Future Perspectives